Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26101059 | 1.00 | GRM2 (0.38) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL3666263 | 1.00 | GRM2 (0.38) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Hydrochloric Acid SCHEMBL1347345 | 0.98 | GRM2 (0.37) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Hydrochloric Acid SCHEMBL15776372 | 0.98 | GRM2 (0.37) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Hydrochloric Acid SCHEMBL6826204 | 0.98 | GRM2 (0.37) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Trifluoroacetic Acid SCHEMBL15129828 | 0.89 | GRM2 (0.36) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL24021079 | 0.80 | GRM2 (0.34) | GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL40622 | 0.80 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL3145095 | 0.80 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL40623 | 0.80 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590670-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025063849-A2 | DIMERIC FAP TARGETING AGENTS | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2025-03-27 | — | — | WO | disclosed |
| US-20240382624-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-09-12 | — | — | US | disclosed |
| WO-2024063648-A1 | Platform and scaffold for FAP targeting agents | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-03-28 | — | — | WO | disclosed |
| EP-4342890-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2024-03-27 | — | — | EP | disclosed |
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024002853-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PRECURSOR AND RADIOTRACER | Positron Precision GmbH (DE) | 2024-01-04 | — | — | WO | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005023762-A1 | PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023762-A1 | PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382624-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | GRM2 4864/4885GRM3 4866/4885CYP1A2 3459/4885 |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | GRM2 1391/4885GRM3 693/4885CYP1A2 4065/4885 |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | MMP1, PIK3CA, AKT2 | GRM2 4201/4885GRM3 4353/4885CYP1A2 2359/4885 |
| US-11872291-B2 | Fibroblast activation protein (FAP)-targeted imaging and therapy | FAP, FIBP, FRS2 | GRM2 4187/4885GRM3 4170/4885CYP1A2 4439/4885 |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | GRM2 4864/4885GRM3 4866/4885CYP1A2 3459/4885 |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | MC5R, MC4R, OPRD1 | GRM2 619/4885GRM3 469/4885CYP1A2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.